Symbol
| CLDN4
| contributors: mct - updated : 21-01-2017
|
HGNC name
| claudin 4
|
HGNC id
| 2046
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --over
|  
|
in colorectal cancer | tumoral
|  
|  
| --over
|  
|
in ovarian carcinoma | tumoral
|  
|  
| --over
|  
|
in intestinal-type gastric cancer ( lower in diffuse-type gasric cancer) | tumoral
|  
|  
| --over
|  
|
in prostate cancer, highly expressed in lower grade lesions than in higher grade | tumoral
|  
|  
| --low
|  
|
in highly aggressive esophageal cancer and the reduction of CLDN4 leads to the resultant disruption of tight junctions that may be associated with EMT | constitutional
|  
|  
| --over
|  
|
in the placentas of diabetic mothers and in toxaemia | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| very useful marker for distinguishing mesothelioma and adenocarcinoma, even if histological specimens are small, as in biopsies that contain limited numbers of tumor cells | |
highly specific and sensitive immunohistochemical marker for assisting in distinguishing epithelioid mesotheliomas from metastatic carcinomas to the serosal membranes (pMID: 23596113) | Therapy target
| |
|
System | Type | Disorder | Pubmed |
cancer | | | |
anti-claudin-3 and -4 bispecific monoclonal antibody shows promise in the development of a diagnostic and therapeutic antibody for cancers | cancer | digestive | colon | |
potential markers and therapy target in colorectal cancer | cancer | reproductive | prostate | |
useful as a potential marker and therapeutic target for prostate cancer metastases |
| |
| progressive hydronephrosis in Cldn4(-/-) mice arises from urinary tract obstruction due to urothelial hyperplasia |